
Larimar Therapeutics fell 15.0% from $3.53 to $3.00, behind the S&P 500's +11.2%. Its worst day was Nov 5 (−15.9%), and its low came Oct 16 at $1.99.
Nov 17, 2025 – Nov 16, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Larimar Therapeutics closed at its highest level of the year, 68.6% above where the year started.
+61.2%, the year's best day, on 81M shares, the year's heaviest volume · S&P 500 +0.8%
Story events cover the past 12 months · Times ET
EPS of $-0.73 missed the $-0.50 estimate on $0.00 revenue.
+4.0% · S&P 500 −0.5%
EPS of $-0.31 beat the $-0.56 estimate on $0.00 revenue.
−5.1% · S&P 500 +0.8%
EPS of $-0.30 beat the $-0.38 estimate on $0.00 revenue.
+3.3% · S&P 500 +1.8%
Larimar Therapeutics closed at its lowest level of the year, 43.8% below where the year started.
−0.3% · S&P 500 −1.1%
Larimar Therapeutics shares fell 15.9%, while the S&P 500 fell 4.4%.
−15.9%, the year's worst day · S&P 500 −4.4%
EPS of $-0.29 beat the $-0.36 estimate on $0.00 revenue.
−0.7% · S&P 500 −1.9%
Where it ended: a close of $3.00 on Nov 16, 2026.
Nothing in the past 12 months.
All LRMR dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for LRMR and SPY from Benzinga historical bars. Not investment advice.